| pubmed-article:10607256 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10607256 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10607256 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:10607256 | lifeskim:mentions | umls-concept:C0524909 | lld:lifeskim |
| pubmed-article:10607256 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:10607256 | lifeskim:mentions | umls-concept:C0076612 | lld:lifeskim |
| pubmed-article:10607256 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:10607256 | lifeskim:mentions | umls-concept:C0599724 | lld:lifeskim |
| pubmed-article:10607256 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:10607256 | pubmed:dateCreated | 2000-7-13 | lld:pubmed |
| pubmed-article:10607256 | pubmed:abstractText | Previous clinical trials have suggested that thymosin alpha1 (Talpha1), an immunomodulatory peptide, may be effective in the treatment of chronic hepatitis B (CHB). The aim of this study was to determine the efficacy of Talpha1 in a multicentre, placebo-controlled and double-blind study of 97 patients with serum hepatitis B virus (HBV) DNA- and hepatitis B e antigen (HBeAg)-positive CHB. Patients who had been hepatitis B surface antigen (HBsAg) positive for at least 12 months entered a 3-month screening period prior to randomization. Forty-nine patients received Talpha1 (1.6 mg) and 48 patients received placebo, twice weekly for 6 months, and were followed-up for an additional 6 months. At inclusion, both groups were comparable for age, gender, histological grading, and aminotransferase and HBV DNA levels. A complete response to treatment, defined as a sustained serum HBV DNA-negative status (two negative results at least 3 months apart) during the 12-month study, with negative HBV DNA and HBeAg values at month 12, was seen in seven (14%) patients given Talpha1 and in two (4%) patients treated with placebo (P = 0.084). Five (10%) patients given Talpha1 and four (8%) patients given placebo exhibited a delayed response (defined as sustained serum HBV DNA negativity achieved after the 12-month study period with negative HBV DNA and HBeAg values at the last assessment). A total of 12 (25%) patients given Talpha1 and six (13%) patients given placebo showed a sustained loss of HBV DNA with a negative HBeAg value during or following the 12-month study period (P < 0.11). These results do not confirm observations of treatment efficacy reported in other clinical studies. | lld:pubmed |
| pubmed-article:10607256 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10607256 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10607256 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10607256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10607256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10607256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10607256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10607256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10607256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10607256 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10607256 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:10607256 | pubmed:issn | 1352-0504 | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:MilsteinSS | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:SilvaMM | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:SchiffE RER | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:CummingsG DGD | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:MutchnickM... | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:AppelmanH DHD | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:GordonS CSC | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:EhrinpreisM... | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:LindsayK LKL | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:PelemanR RRR | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:SimmonsFF | lld:pubmed |
| pubmed-article:10607256 | pubmed:author | pubmed-author:RoachK CKC | lld:pubmed |
| pubmed-article:10607256 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10607256 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:10607256 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10607256 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10607256 | pubmed:pagination | 397-403 | lld:pubmed |
| pubmed-article:10607256 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:meshHeading | pubmed-meshheading:10607256... | lld:pubmed |
| pubmed-article:10607256 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10607256 | pubmed:articleTitle | Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. | lld:pubmed |
| pubmed-article:10607256 | pubmed:affiliation | Division of Gastroenterology, Department of Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA. | lld:pubmed |
| pubmed-article:10607256 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10607256 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10607256 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10607256 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:10607256 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:10607256 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10607256 | lld:pubmed |
